UNSPSC 51101641: Buparvaquone

This classification denotes an antiprotozoal agent with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0354RT7LG4, chemically known as 1,4-naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy- but generally known as buparvaquone, which bears US NIH Compound Identifier 71768. European Medicines Agency schedules Buparvaquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05980MIG.

UNSPSC 51101641 Buparvaquone is a Commodity code that nominally designates a specific veterinary pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with the code's stated scope. The two opportunities posted in 2026 involve human pharmaceutical supplies — antibiotic tablets for pandemic preparedness through a cooperative purchasing vehicle, and naloxone plus drug deactivation systems for community health — neither of which involves buparvaquone or veterinary pharmaceuticals. State and local governments do solicit pharmaceutical supplies through UNSPSC taxonomy, but the recent records tagged to this code do not reflect purchases of buparvaquone itself. The issuing bodies in the recent opportunities include a state health department and a county government, both pursuing supplies through competitive bidding or cooperative-purchasing piggyback arrangements.

The geographic activity is limited: the Illinois Department of Public Health posted a piggyback pharmaceutical warehouse order through the MMCAP Infuse consortium on August 28, 2026 (awarded to Chartwell Rx LLC for $2,999,999.11 over the contract life, with a 12-month initial term and renewal options), and Seminole County, Florida issued an IFB for naloxone and drug deactivation systems on June 30, 2026 with a response deadline of July 26, 2026 (1,900 units of naloxone and 800 deactivation systems annually, with quarterly delivery to the county health building in Sanford). The code shows minimal recent activity, and the opportunities posted do not reflect the pharmaceutical product designated by the UNSPSC number itself. Buyers pursuing this code should confirm category alignment with issuing bodies or consider whether pharmaceutical procurement falls under broader family-level codes instead.